LLY

884.96

-0.04%↓

NVO

141.87

+0.6%↑

UNH

482.42

-0.43%↓

JNJ

148.65

+0.6%↑

MRK

130.24

+0.4%↑

LLY

884.96

-0.04%↓

NVO

141.87

+0.6%↑

UNH

482.42

-0.43%↓

JNJ

148.65

+0.6%↑

MRK

130.24

+0.4%↑

LLY

884.96

-0.04%↓

NVO

141.87

+0.6%↑

UNH

482.42

-0.43%↓

JNJ

148.65

+0.6%↑

MRK

130.24

+0.4%↑

LLY

884.96

-0.04%↓

NVO

141.87

+0.6%↑

UNH

482.42

-0.43%↓

JNJ

148.65

+0.6%↑

MRK

130.24

+0.4%↑

LLY

884.96

-0.04%↓

NVO

141.87

+0.6%↑

UNH

482.42

-0.43%↓

JNJ

148.65

+0.6%↑

MRK

130.24

+0.4%↑

Search

Bio-Techne Corp

Closed

Sector Healthcare

73.68 -1.19

Overview

Share price change

24h

Current

Min

73.34

Max

73.95

Key metrics

By Trading Economics

Income

22M

49M

Sales

303B

303B

P/E

Sector Avg

50.636

23.904

EPS

0.48

Dividend yield

0.392

Profit margin

0.016

Employees

3,050

EBITDA

8.2M

92M

Recommendations

By TipRanks

Recommendations

Buy

12 Months Forecast

+11.32 upside

Dividends

By Dow Jones

Dividend yield

Sector Avg

0.39%

7.76%

Next Earnings

6 sie 2024

Next Dividend date

30 sie 2024

Next Ex Dividend date

15 sie 2024

Market Stats

By TradingEconomics

Market Cap

-468M

12B

Previous open

74.87

Previous close

73.68

News Sentiment

By Acuity

50%

50%

98 / 369 Ranking in Healthcare

Technical Score

By Trading Central

Confidence

Bearish Evidence

Bio-Techne Corp Chart

Related News

21 cze 2024, 17:53 UTC

Major Market Movers

Shares of Four U.S. Banks Slide as Regulator Finds Living Wills Weaknesses

22 cze 2024, 23:00 UTC

Earnings

The Crazy Economics of the World's Most Coveted Handbag -- WSJ

22 cze 2024, 23:00 UTC

Earnings

The Crazy Economics of the World's Most Coveted Handbag -- WSJ -2-

22 cze 2024, 10:00 UTC

Top News
Earnings

Nvidia Is No Cisco, but It Is Getting Expensive -- Heard on the Street -- WSJ

22 cze 2024, 09:30 UTC

Earnings

Delivery Drivers Got Higher Wages. Now They're Getting Fewer Orders. -- WSJ

22 cze 2024, 08:20 UTC

Market Talk

Financial Services Roundup: Market Talk

21 cze 2024, 23:45 UTC

Acquisitions, Mergers, Takeovers

Nvidia Is Surging. Why That's a Problem for a Tech ETF. -- Barrons.com

21 cze 2024, 22:19 UTC

Top News

Jury Convicts Milken Protégé Terren Peizer of Insider Trading -- WSJ

21 cze 2024, 20:50 UTC

Market Talk

Financial Services Roundup: Market Talk

21 cze 2024, 20:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

21 cze 2024, 20:37 UTC

Top News

S&P 500 Clinches Third Straight Weekly Gain -- WSJ

21 cze 2024, 20:08 UTC

Top News

Apple Says Regulatory Concerns Might Prevent Rollout of AI Features in Europe -- Update

21 cze 2024, 19:22 UTC

Market Talk

Oil Futures Post Weekly Gain on Demand Expectations -- Market Talk

21 cze 2024, 19:04 UTC

Market Talk

Higher Output, Easing Heat Pressure U.S. Natural Gas -- Market Talk

21 cze 2024, 18:53 UTC

Market Talk
Acquisitions, Mergers, Takeovers

Home Depot to Benefit from Diversified Consumer Base After Latest Acquisition -- Market Talk

21 cze 2024, 18:41 UTC

Market Talk

Gold Slides in Cautious Market -- Market Talk

21 cze 2024, 18:41 UTC

Market Talk

Global Equities Roundup: Market Talk

21 cze 2024, 18:34 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

21 cze 2024, 18:34 UTC

Market Talk

Mexico's Peso Gets Lift From Picks for New Cabinet -- Market Talk

21 cze 2024, 17:53 UTC

Earnings

Delta Stock Is a Winner. Its CEO Explains Why It Can Fly Higher. -- Barrons.com

21 cze 2024, 17:43 UTC

Market Talk

U.S. Oil Rig Count Falls to 485 -- Market Talk

21 cze 2024, 17:32 UTC

Top News

Apple Says Regulatory Concerns May Prevent Rollout of AI Features in Europe -- WSJ

21 cze 2024, 17:16 UTC

Acquisitions, Mergers, Takeovers

Penn Could be Getting a Buyout Offer. Wall Street Doesn't Agree on What It Means for the Stock. -- Barrons.com

21 cze 2024, 17:06 UTC

Top News

Regulators Cite Big Banks, Including Goldman Sachs and JPMorgan, Over Living Wills -- WSJ

21 cze 2024, 16:29 UTC

Market Talk

Strong USD a Pressure Point for Grains -- Market Talk

21 cze 2024, 16:20 UTC

Market Talk

Basic Materials Roundup: Market Talk

21 cze 2024, 16:15 UTC

Market Talk

Global Commodities Roundup: Market Talk

21 cze 2024, 15:46 UTC

Market Talk

Gold Futures Slump as Strong U.S. Business Activity Boosts Dollar -- Market Talk

21 cze 2024, 15:40 UTC

Market Talk

Citi Sees Chance of Sustained Oil Price Rally -- Market Talk

21 cze 2024, 15:30 UTC

Market Talk

Canadian Core Retail Sales Rebound in April Seen as Encouraging -- Market Talk

Peer Comparison

Price change

Bio-Techne Corp Forecast

Price Target

By TipRanks

11.32% upside

12 Months Forecast

Average 82 USD  11.32%

High 95 USD

Low 65 USD

Based on 9 Wall Street analysts offering 12 month price targets forBio-Techne Corp - Dist in the last 3 months.

Rating Consensus

By TipRanks

Buy

9 ratings

6

Buy

3

Hold

0

Sell

Technical Score

By Trading Central

73.43 / 75.88Support & Resistance

Short Term

Bearish Evidence

Intermediate Term

Strong Bullish Evidence

Long Term

Weak Bearish Evidence

Sentiment

By Acuity

98 / 369 Ranking in Healthcare

News Sentiment

Neutral

Volatility

Below average

News Volume (RCV)

Below average

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

$

About Bio-Techne Corp

Bio-Techne Corporation is a developer, manufacturer, and seller of life science reagents, instruments and services for the research, diagnostics, and bioprocessing markets. The Company operates through two segments: Protein Sciences and Diagnostics and Genomics. The Protein Sciences segment is a developer and manufacturer of biological reagents used in all aspects of life science research, diagnostics and cell and gene therapy. This segment also includes proteomic analytical tools, both manual and automated, that offer researchers and pharmaceutical manufacturers efficient options for automated western blot and multiplexed ELISA workflow. The Diagnostics and Genomics segment develops and manufactures diagnostic products, including controls, calibrators, and diagnostic assays for the regulated diagnostics market, exosome-based molecular diagnostic assays, advanced tissue-based in-situ hybridization assays for spatial genomic and tissue biopsy analysis, and genetic and oncology kits.